Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) shares rose 4.2% during mid-day trading on Wednesday . The stock traded as high as $26.22 and last traded at $26.14, with a volume of 314,118 shares traded. The stock had previously closed at $25.08.

ALDR has been the topic of a number of research reports. Wells Fargo & Co. initiated coverage on shares of Alder BioPharmaceuticals in a research report on Thursday, April 21st. They set an “outperform” rating on the stock. Jefferies Group restated a “buy” rating and set a $61.00 target price on shares of Alder BioPharmaceuticals in a research report on Thursday, June 9th. Brean Capital initiated coverage on shares of Alder BioPharmaceuticals in a research report on Wednesday, April 20th. They set a “buy” rating and a $45.00 target price on the stock. Credit Suisse Group AG restated an “outperform” rating and set a $40.00 target price on shares of Alder BioPharmaceuticals in a research report on Tuesday, March 29th. Finally, Zacks Investment Research upgraded shares of Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 30th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $52.00.

The firm’s market capitalization is $1.33 billion. The firm has a 50-day moving average of $27.65 and a 200 day moving average of $25.72.

Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported ($0.76) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.72) by $0.04. During the same period in the prior year, the business earned ($0.40) earnings per share. Equities analysts predict that Alder BioPharmaceuticals Inc. will post ($3.25) earnings per share for the current fiscal year.

In related news, VP Jeffrey T. L. Smith sold 16,090 shares of Alder BioPharmaceuticals stock in a transaction that occurred on Friday, June 3rd. The stock was sold at an average price of $30.20, for a total value of $485,918.00. Following the transaction, the vice president now directly owns 16,090 shares of the company’s stock, valued at $485,918. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Mark James Litton sold 6,000 shares of Alder BioPharmaceuticals stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $28.94, for a total value of $173,640.00. Following the completion of the transaction, the insider now directly owns 74,567 shares in the company, valued at $2,157,968.98. The disclosure for this sale can be found here.

Several institutional investors recently bought and sold shares of ALDR. Brown Advisory Inc. raised its position in Alder BioPharmaceuticals by 118.8% in the fourth quarter. Brown Advisory Inc. now owns 379,579 shares of the biopharmaceutical company’s stock worth $12,538,000 after buying an additional 206,108 shares in the last quarter. ProShare Advisors LLC raised its position in Alder BioPharmaceuticals by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 38,476 shares of the biopharmaceutical company’s stock worth $1,271,000 after buying an additional 3,058 shares in the last quarter. Pyrrho Capital Management LP raised its position in Alder BioPharmaceuticals by 205.0% in the fourth quarter. Pyrrho Capital Management LP now owns 63,000 shares of the biopharmaceutical company’s stock worth $2,081,000 after buying an additional 42,343 shares in the last quarter. Janus Capital Management raised its position in Alder BioPharmaceuticals by 391.1% in the third quarter. Janus Capital Management now owns 4,239,855 shares of the biopharmaceutical company’s stock worth $138,900,000 after buying an additional 3,376,540 shares in the last quarter. Finally, Nationwide Fund Advisors raised its position in Alder BioPharmaceuticals by 103.6% in the fourth quarter. Nationwide Fund Advisors now owns 30,380 shares of the biopharmaceutical company’s stock worth $1,003,000 after buying an additional 15,457 shares in the last quarter.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.